Crossmark

Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

Crossref DOI link: https://doi.org/10.1038/s41416-020-01239-z

Published Online: 2021-02-03

Published Print: 2021-03-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zalba, Sara

Belsúe, Virginia

Topp, Brian

de Alwis, Dinesh

Alvarez, Maite http://orcid.org/0000-0002-5969-9181
Trocóniz, Iñaki F. http://orcid.org/0000-0003-3700-8658
Berraondo, Pedro

Garrido, María J. http://orcid.org/0000-0003-3559-4710
License Information

Text and Data Mining valid from 2021-02-03

Version of Record valid from 2021-02-03
More Information

Article History

Received: 20 May 2020

Revised: 5 November 2020

Accepted: 10 December 2020

First Online: 3 February 2021

Ethics approval and consent to participate

: All in vivo experiments were performed according to European animal care regulations and to the protocol approved by the Ethics Committee of the University of Navarra (Ref. 023-17).

: Not applicable.

: The datasets used during the current study are available from the corresponding author on reasonable request.

: B.T. and D.d.A. are currently working in Merck & Co. The other authors have no further conflict of interests.

: This work has been financed by Merck & Co. and Instituto de Salud Carlos III (PI19/01128) co-financed by Fondos Feder and Joint Translational Call for Proposals 2015 (JTC 2015) TRANSCAN-2 (code: TRS-2016-00000371). P.B. was supported by the Spanish Society Against Cancer Investigator Award (INVES19041ALVA).

Document is current

Any future updates will be listed below